What is the global market size of Hyperphosphatemia Therapeutics Market?

Global Hyperphosphatemia Therapeutics Market size was valued at USD 3.1 billion in 2021 and is poised to grow from USD 3.3 billion in 2022 to USD 4.2 billion by 2030, growing at a CAGR of 6.5% in the forecast period (2023-2030).

Hyperphosphatemia Therapeutics Market Size, Share, Growth Analysis, By Product Type(Sevelamer, Calcium-based Phosphate Blinders, Iron-based Phosphate Binders, Lanthanum Carbonate), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2024-2031

Q: Who are the key vendors in the Global Hyperphosphatemia Therapeutics Market?

The Global Hyperphosphatemia Therapeutics Market is highly fragmented due to the strong presence of a large number of players. As a result, the global Hyperphosphatemia Therapeutics market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology. 'Sanofi Genzyme', 'Keryx Biopharmaceuticals, Inc.', 'Fresenius Medical Care AG & Co. KGaA', 'Vifor Pharma Management Ltd.', 'Amgen Inc.', 'F. Hoffmann-La Roche Ltd.', 'AstraZeneca plc', 'Pfizer Inc.', 'Relypsa, Inc.', 'Ardelyx, Inc.', 'Velphoro (Fresenius Medical Care AG & Co. KGaA)', 'Phoslyra (Fresenius Medical Care AG & Co. KGaA)', 'Renvela/Renagel (Sanofi Genzyme)', 'Fosrenol (Shire)', 'Kayexalate (Sanofi Genzyme)', 'Ferumoxytol (AMAG Pharmaceuticals, Inc.)', 'Etelcalcetide (Amgen Inc.)', 'Parsabiv (Amgen Inc.)', 'Patiromer (Relypsa, Inc.)', 'Sucroferric Oxyhydroxide (Vifor Pharma Management Ltd.)'

Report ID: SQSG35I2014 | Region: Global | Published Date: April, 2024
Pages: 157 | Tables: 66 | Figures: 75

Hyperphosphatemia Therapeutics Market Regional Insights

The Global Hyperphosphatemia Therapeutics Market is segmented based on geography as North America, Europe, Asia-Pacific, Latin America, and MEA. Among these regions, the North American region held a significant share in the market, which is followed by Europe, Asia Pacific, Latin America, the Middle East, and Africa. The dominance of North America can be attributed in terms of income, North America is by far the market leader for medications for hyperphosphatemia worldwide. The rising prevalence of diabetes and osteoporosis as well as many chronic renal diseases are driving the market for hyperphosphatemia therapeutics in North America. The market is expanding at the fastest rate in Asia-Pacific. In terms of income and size, China is anticipated to be the Asia-Pacific region's largest market. It is anticipated that demand for hyperphosphatemia medications in China will be fuelled by the increasing healthcare infrastructure across the nation, spurred by the country's central government's robust growth initiatives.

Hyperphosphatemia Therapeutics Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Hyperphosphatemia Therapeutics Market size was valued at USD 3.1 billion in 2019 and is poised to grow from USD 3.3 billion in 2023 to USD 4.2 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

The Hyperphosphatemia Therapeutics Market is highly fragmented due to the strong presence of a large number of players. As a result, the Hyperphosphatemia Therapeutics market has been witnessing the constant entry of new players over the years. In order to sustain the highly competitive environment, existing players differentiate themselves through innovation, quality, and technology. 'Sanofi Genzyme', 'Keryx Biopharmaceuticals, Inc.', 'Fresenius Medical Care AG & Co. KGaA', 'Vifor Pharma Management Ltd.', 'Amgen Inc.', 'F. Hoffmann-La Roche Ltd.', 'AstraZeneca plc', 'Pfizer Inc.', 'Relypsa, Inc.', 'Ardelyx, Inc.', 'Velphoro (Fresenius Medical Care AG & Co. KGaA)', 'Phoslyra (Fresenius Medical Care AG & Co. KGaA)', 'Renvela/Renagel (Sanofi Genzyme)', 'Fosrenol (Shire)', 'Kayexalate (Sanofi Genzyme)', 'Ferumoxytol (AMAG Pharmaceuticals, Inc.)', 'Etelcalcetide (Amgen Inc.)', 'Parsabiv (Amgen Inc.)', 'Patiromer (Relypsa, Inc.)', 'Sucroferric Oxyhydroxide (Vifor Pharma Management Ltd.)'

The increasing prevalence of chronic renal disease worldwide is one of the key factors propelling the market's growth. Due to its expanding impact, it is predicted that by 2040, chronic kidney disease (CKD) would rank as the fifth most common cause of years lost globally. The overall number of individuals receiving dialysis has increased globally as a result of the rising prevalence of CKD. 785,883 Americans needed kidney transplants and dialysis in 2018, according to the National Kidney Foundation Inc. Of these people, dialysis was utilized to replace renal function in 554 338 cases. Nearly all dialysis-dependent renal failure patients experience hyperphosphatemia at some point in their lives. Additionally, according to the National Center for Biotechnology Information (NCBI), phosphate binders are used to treat 80–85% of dialysis patients who have hyperphosphatemia. Therefore, the market's growth during the forecast period will be greatly supported by the rising prevalence of chronic renal diseases.

A shift towards the adoption of non-phosphate binders is the key trend in the market. It is quite difficult to achieve ideal phosphate management in CKD patients receiving dialysis. The ability to manage phosphate levels in dialysis patients has not significantly improved despite the advancements in dialysis procedures throughout the years. Phosphate binders also have a number of negative side effects. Researchers are therefore concentrating on the development of novel hyperphosphatemia medicines and revising the treatment recommendations in order to improve the therapy choice for hyperphosphatemia. Phosphate binders are expected to be replaced by non-phosphate binders in the treatment of hyperphosphatemia, such as Tenapanor, an inhibitor of the hydrogen/sodium exchanger isoform 3 (NHE3).

The Hyperphosphatemia Therapeutics Market is segmented based on geography as North America, Europe, Asia-Pacific, Latin America, and MEA. Among these regions, the North American region held a significant share in the market, which is followed by Europe, Asia Pacific, Latin America, the Middle East, and Africa. The dominance of North America can be attributed in terms of income, North America is by far the market leader for medications for hyperphosphatemia worldwide. The rising prevalence of diabetes and osteoporosis as well as many chronic renal diseases are driving the market for hyperphosphatemia therapeutics in North America. The market is expanding at the fastest rate in Asia-Pacific. In terms of income and size, China is anticipated to be the Asia-Pacific region's largest market. It is anticipated that demand for hyperphosphatemia medications in China will be fuelled by the increasing healthcare infrastructure across the nation, spurred by the country's central government's robust growth initiatives.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Hyperphosphatemia Therapeutics Market Regional Insights

Hyperphosphatemia Therapeutics Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Hyperphosphatemia Therapeutics Market?

Who are the key vendors in the Hyperphosphatemia Therapeutics Market?

What is the key driver of Hyperphosphatemia Therapeutics Market?

What is the key market trend for Hyperphosphatemia Therapeutics Market?

Which region accounted for the largest share in Hyperphosphatemia Therapeutics Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300